Shots:

• The approval is based on a DAPA-HF trial assessing Forxiga (10mg- qd) + SOC vs PBO + SOC in 4-744 patients with HFrEF (LVEF ≤ 40%) with/ out T2D
• The study demonstrated reduced the risk of the composite outcome by 26% along with a reduction in the risk of CV death or worsening of HF events- including hospitalization for HF
• Additionally- Forxiga is currently being tested for HFpEF in the P-III DELIVER trial with data readout anticipated in the H2’21

­ Ref: PRNewswire | Image: Mint